{
  "folder": "IC-075",
  "content": "{{knowledge objective\n|Identifiant=OIC-075-31-B\n|Item_parent=Smoking addiction\n|Item_parent_short=Smoking addiction\n|Rank=B\n|Title=Knowing about medication other than nicotine replacement therapy\n|Description=Varenicline and Bupropion\n|Rubric=Management\n|Contributors=\n|Order=31}}\nAfter nicotine replacement therapy, Varenicline can be offered as a second-line treatment, followed by Bupropion as a last-line treatment.\n\n'''Varenicline''' :\n\n* Partial agonist of nicotinic acetylcholine receptors.\n* Indicated in cases of failure of nicotine replacement therapy and strong nicotine dependence.\n* The main side effects are nausea, headaches, nightmares, insomnia, depression and cardiovascular risk.\n* Reimbursed by health insurance\n\n'''Bupropion''' :\n\n* Noradrenaline and dopamine reuptake inhibitor\n\n<br />",
  "question": {
    "properties": {
      "question": "What is the primary mechanism of action for Bupropion in smoking cessation?",
      "option_a": "Partial agonist of nicotinic acetylcholine receptors",
      "option_b": "Noradrenaline and dopamine reuptake inhibitor",
      "option_c": "Inhibitor of cytochrome P450 enzymes",
      "option_d": "Selective serotonin reuptake enhancer",
      "correct_option": "B"
    },
    "required": [
      "question",
      "option_a",
      "option_b",
      "option_c",
      "option_d",
      "correct_option"
    ]
  }
}